@article{JTD17832,
author = {Magdalena Drzewiecka-Jędrzejczyk and Rafał Wlazeł and Monika Terlecka and Sławomir Jabłoński},
title = {Serum metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in lung carcinoma patients},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {12},
year = {2017},
keywords = {},
abstract = {Background: Assessment of serum extracellular matrix (ECM) metalloproteinase MMP-2 and tissue inhibitor of matrix metalloproteinase TIMP-2 concentrations in non-small cell lung carcinoma (NSCLC) patients considering TNM staging. Assessment of the prognostic value of MMP-2 and TIMP-2 concentrations in NSCLC patients.
Methods: The study group consisted of 81 NSCLC patients (24 females and 57 males) aged 46 to 86 years (mean age of 67±8.2 years). The control group comprised 39 randomly selected patients (20 females and 19 males) aged 27 to 73 years (mean age of 47±15.0 years) in whom primary lung cancer was excluded and who were operated on for a calculus of the gallbladder without cholecystitis. Blood serum MMP-2 and TIMP-2 concentrations were determined using an enzyme-linked immunosorbent assay (ELISA)-based test.
Results: Statistically significantly higher mean MMP-2 and TIMP-2 concentrations were found in NSCLC patients compared to those in the control group (P},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/17832}
}